SpecifEx-Hep B

Drug Profile

SpecifEx-Hep B

Alternative Names: Hepatitis B virus-specific cytotoxic T lymphocytes

Latest Information Update: 08 Aug 2007

Price : $50

At a glance

  • Originator CellExSys
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B

Most Recent Events

  • 31 Jan 2007 Discontinued - Preclinical for Hepatitis B treatment in USA (Infusion)
  • 10 Aug 2004 CellExSys has been acquired by Chromos Molecular Systems
  • 09 Jul 2003 Preclinical trials in Hepatitis B treatment in USA (Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top